Rhumbline Advisers Has $6.05 Million Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Rhumbline Advisers cut its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 4.7% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,123 shares of the medical instruments supplier's stock after selling 3,538 shares during the period. Rhumbline Advisers owned approximately 0.32% of LeMaitre Vascular worth $6,051,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Smartleaf Asset Management LLC grew its holdings in shares of LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 293 shares in the last quarter. CBIZ Investment Advisory Services LLC raised its stake in shares of LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after purchasing an additional 117 shares in the last quarter. Huntington National Bank lifted its holdings in shares of LeMaitre Vascular by 64.9% during the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after buying an additional 455 shares during the last quarter. Empowered Funds LLC acquired a new position in LeMaitre Vascular in the fourth quarter worth approximately $150,000. Finally, Canada Pension Plan Investment Board raised its position in LeMaitre Vascular by 112.5% during the fourth quarter. Canada Pension Plan Investment Board now owns 1,700 shares of the medical instruments supplier's stock valued at $157,000 after acquiring an additional 900 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Stock Performance

Shares of LMAT traded down $1.77 during mid-day trading on Thursday, hitting $81.37. The company's stock had a trading volume of 103,908 shares, compared to its average volume of 168,489. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $109.58. The stock's 50-day moving average is $83.75 and its two-hundred day moving average is $90.64. The firm has a market capitalization of $1.84 billion, a PE ratio of 44.46, a price-to-earnings-growth ratio of 2.22 and a beta of 0.83.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. During the same period in the prior year, the company posted $0.44 EPS. The firm's quarterly revenue was up 12.0% on a year-over-year basis. Analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were paid a $0.20 dividend. The ex-dividend date was Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. LeMaitre Vascular's payout ratio is 40.40%.

Analyst Upgrades and Downgrades

Several research firms have commented on LMAT. Lake Street Capital boosted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Oppenheimer cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price on the stock. Finally, Barrington Research cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $97.83.

Insider Buying and Selling

In other news, CEO George W. Lemaitre sold 18,733 shares of the stock in a transaction on Friday, May 16th. The shares were sold at an average price of $84.77, for a total value of $1,587,996.41. Following the completion of the transaction, the chief executive officer now owns 1,873,651 shares in the company, valued at approximately $158,829,395.27. This represents a 0.99% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 100,000 shares of company stock valued at $8,556,857 over the last ninety days. 9.50% of the stock is owned by company insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.